Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
Total Valuation
Madrigal Pharmaceuticals has a market cap or net worth of $9.91B. The enterprise value is $9.54B.
Market Cap$9.91B
Enterprise Value$9.54B
Share Statistics
Madrigal Pharmaceuticals has 22,289,015 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,289,015
Owned by Insiders20.04%
Owned by Institutions<0.01%
Financial Efficiency
Madrigal Pharmaceuticals’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -56.97%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-56.97%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee341.16K
Profits Per Employee-882.37K
Employee Count528
Asset Turnover0.17
Inventory Turnover0.22
Valuation Ratios
The current PE Ratio of Madrigal Pharmaceuticals is ―. Madrigal Pharmaceuticals’s PEG ratio is -1.47.
PE Ratio―
PS Ratio36.44
PB Ratio8.70
Price to Fair Value8.70
Price to FCF-14.36
Price to Operating Cash Flow-32.12
PEG Ratio-1.47
Income Statement
In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M and earned -465.89M in profits. Earnings per share was -21.90.
Revenue180.13M
Gross Profit172.80M
Operating Income-497.88M
Pretax Income-465.89M
Net Income-465.89M
EBITDA-450.13M
Earnings Per Share (EPS)-21.90
Cash Flow
In the last 12 months, operating cash flow was -160.58M and capital expenditures -1.05M, giving a free cash flow of -161.63M billion.
Operating Cash Flow-160.58M
Free Cash Flow-161.63M
Free Cash Flow per Share-7.25
Dividends & Yields
Madrigal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change43.43%
50-Day Moving Average435.20
200-Day Moving Average348.76
Relative Strength Index (RSI)67.70
Average Volume (3m)38.00
Important Dates
Madrigal Pharmaceuticals upcoming earnings date is Mar 4, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend Date―
Financial Position
Madrigal Pharmaceuticals as a current ratio of 6.10, with Debt / Equity ratio of 17.81%
Current Ratio6.10
Quick Ratio5.90
Debt to Market Cap0.02
Net Debt to EBITDA-0.04
Interest Coverage Ratio-33.94
Taxes
In the past 12 months, Madrigal Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Madrigal Pharmaceuticals EV to EBITDA ratio is -14.63, with an EV/FCF ratio of -14.41.
EV to Sales36.55
EV to EBITDA-14.63
EV to Free Cash Flow-14.41
EV to Operating Cash Flow-14.45
Balance Sheet
Madrigal Pharmaceuticals has $1.11B in cash and marketable securities with $1.08M in debt, giving a net cash position of $1.11B billion.
Cash & Marketable Securities$1.11B
Total Debt$1.08M
Net Cash$1.11B
Net Cash Per Share$49.74
Tangible Book Value Per Share$35.24
Margins
Gross margin is 96.01%, with operating margin of -276.39%, and net profit margin of -258.64%.
Gross Margin96.01%
Operating Margin-276.39%
Pretax Margin-258.64%
Net Profit Margin-258.64%
EBITDA Margin-249.88%
EBIT Margin-250.49%
Analyst Forecast
The average price target for Madrigal Pharmaceuticals is $519.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$519.64
Price Target Upside7.01% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast―
EPS Growth Forecast―